KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Raw Materials (2016 - 2019)

Jazz Pharmaceuticals (JAZZ) has 10 years of Raw Materials data on record, last reported at $7.1 million in Q1 2019.

  • For Q1 2019, Raw Materials changed N/A year-over-year to $7.1 million; the TTM value through Mar 2019 reached $7.1 million, changed N/A, while the annual FY2018 figure was $5.6 million, 58.22% up from the prior year.
  • Raw Materials reached $7.1 million in Q1 2019 per JAZZ's latest filing, up from $5.6 million in the prior quarter.
  • Across five years, Raw Materials topped out at $7.1 million in Q1 2019 and bottomed at $1.5 million in Q4 2016.
  • Average Raw Materials over 5 years is $3.6 million, with a median of $2.7 million recorded in 2016.
  • Peak YoY movement for Raw Materials: crashed 40.68% in 2016, then soared 128.96% in 2017.
  • A 5-year view of Raw Materials shows it stood at $2.6 million in 2015, then plummeted by 40.68% to $1.5 million in 2016, then soared by 128.96% to $3.5 million in 2017, then surged by 58.22% to $5.6 million in 2018, then increased by 27.37% to $7.1 million in 2019.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $7.1 million in Q1 2019, $5.6 million in Q4 2018, and $4.2 million in Q2 2018.